A single-arm study of the efficacy of pemafibrate in patients with NAFLD (non-alcoholic fatty liver disease) complicated by dyslipidemia
Not Applicable
- Conditions
- AFLD (non-alcoholic fatty liver disease) complicated by dyslipidemia
- Registration Number
- JPRN-UMIN000049937
- Lead Sponsor
- ippon Medical School, gastroenterology, Hiroki Ono
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 91
Inclusion Criteria
Not provided
Exclusion Criteria
The main exclusion criteria were as follows: (1) age <20\x{2009}years; (2) new administration of vitamin E, pioglitazone, SGLT2-Is, and GLP-1 RA known to be potentially effective for NAFLD and other antilipidemic agents within 12\x{2009}weeks prior to pemafibrate treatment; (3) decompensated cirrhosis; and (4) pregnancy or lactation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pemafibrate's efficacy in NAFLD with dyslipidemia?
How does pemafibrate compare to fibrates and other lipid-lowering agents in NAFLD treatment?
Which biomarkers correlate with pemafibrate response in patients with NAFLD and mixed dyslipidemia?
What are the safety profiles of pemafibrate in NAFLD patients with metabolic syndrome?
Are there combination therapies involving pemafibrate for NASH management in dyslipidemic populations?